Veradermics (NYSE:MANE) Stock Price Expected to Rise, Citigroup Analyst Says

Veradermics (NYSE:MANE) had its price objective raised by Citigroup from $160.00 to $175.00 in a research note issued on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Citigroup‘s price target indicates a potential upside of 17.67% from the stock’s current price.

A number of other equities research analysts have also recently commented on MANE. Wall Street Zen raised shares of Veradermics from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Cantor Fitzgerald reissued an “overweight” rating on shares of Veradermics in a report on Monday, October 19th. UBS Group set a $204.00 price target on Veradermics in a research report on Thursday, October 22nd. Leerink Partners upped their price objective on Veradermics from $135.00 to $150.00 and gave the company an “outperform” rating in a research note on Monday. Finally, B. Riley Financial increased their price objective on Veradermics from $170.00 to $204.00 and gave the stock a “buy” rating in a research report on Thursday, October 22nd. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $174.57.

Veradermics Price Performance

Shares of MANE traded up $4.76 during mid-day trading on Tuesday, reaching $148.72. 360,002 shares of the company’s stock were exchanged, compared to its average volume of 640,036. The business’s fifty day simple moving average is $118.66 and its 200-day simple moving average is $97.43. The stock has a market capitalization of $6.21 billion and a PE ratio of -78.29. Veradermics has a 52-week low of $32.00 and a 52-week high of $152.82.

Veradermics (NYSE:MANE) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.50) EPS for the quarter. Equities research analysts predict that Veradermics will post -2.87 earnings per share for the current year.

Insider Activity

In other news, Director John Childs sold 100,000 shares of the firm’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $107.12, for a total value of $10,712,000.00. Following the completion of the sale, the director owned 194,117 shares in the company, valued at approximately $20,793,813.04. This trade represents a 34.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Montanova Capital, Llc sold 750,000 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $107.25, for a total transaction of $80,437,500.00. Following the completion of the sale, the director owned 461,033 shares of the company’s stock, valued at $49,445,789.25. This trade represents a 61.93% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 961,000 shares of company stock worth $103,120,220 in the last 90 days.

Institutional Investors Weigh In On Veradermics

A number of institutional investors have recently added to or reduced their stakes in MANE. Nvwm LLC grew its holdings in Veradermics by 105.4% during the third quarter. Nvwm LLC now owns 228 shares of the company’s stock worth $28,000 after acquiring an additional 117 shares during the period. Sterling Capital Management LLC raised its position in Veradermics by 233.2% in the third quarter. Sterling Capital Management LLC now owns 633 shares of the company’s stock worth $77,000 after acquiring an additional 443 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in Veradermics by 8.4% in the third quarter. Russell Investments Group Ltd. now owns 1,905 shares of the company’s stock valued at $231,000 after acquiring an additional 147 shares during the period. Pictet Asset Management Holding SA lifted its holdings in Veradermics by 22.0% in the third quarter. Pictet Asset Management Holding SA now owns 2,491 shares of the company’s stock valued at $302,000 after acquiring an additional 449 shares during the period. Finally, Arizona State Retirement System purchased a new stake in shares of Veradermics during the 2nd quarter worth $524,000.

Key Veradermics News

Here are the key news stories impacting Veradermics this week:

• Positive Sentiment: Veradermics reported positive 12-month results from Part B of Phase 3 Study 302 in men with pattern hair loss, including the highest hair-count result reported in its VDPHL01 Phase 3 program to date. The clinical progress may strengthen the candidate’s commercial prospects. Article: Veradermics Achieved the Highest VDPHL01 Reported Hair Count
• Positive Sentiment: Leerink Partners raised its price target from $135 to $150 and maintained an Outperform rating, signaling continued analyst optimism, though the revised target implies limited upside relative to the price cited in the report. Analyst rating information
• Neutral Sentiment: Veradermics reported a third-quarter 2026 loss of $0.50 per share. The available report does not provide an analyst-consensus comparison, making the earnings result’s surprise impact unclear. Article: Veradermics Reports Third Quarter 2026 Results

Veradermics Company Profile

Veradermics is a clinical-stage biopharmaceutical company focused on developing treatments for hair loss. Its lead candidate, VDPHL01, is an investigational oral formulation of minoxidil being studied for androgenetic alopecia, commonly known as male- or female-pattern hair loss. The company has described the treatment as designed for once-daily use. VDPHL01 remains under clinical investigation and is not an approved treatment. Veradermics is led by founder and Chief Executive Officer Reid Waldman, a physician specializing in dermatology.